Eris Lifesciences Allots 23.06 Lakh Shares for Swiss Parenterals Acquisition
Eris Lifesciences allotted 23,06,372 equity shares at ₹1835.35 each to Mr. Naishadh Shah. This is for acquiring 16,74,493 shares of Swiss Parenterals, making it a wholly-owned subsidiary. The company's paid-up capital increased to ₹13.85 crore.
The preferential allotment and acquisition of a subsidiary are significant corporate actions that can impact the company's structure and future performance, warranting a medium impact.
The allotment of shares for acquisition and subsequent increase in paid-up capital signifies business expansion and strategic growth for the company.
Eris Lifesciences Limited announced the allotment of 23,06,372 equity shares of face value Re. 1 each, at an issue price of ₹1835.35 per share, including a premium of ₹1834.35. This allotment is on a preferential basis through private placement to Mr. Naishadh Shah.
The allotment is in consideration for the acquisition of 16,74,493 equity shares of Swiss Parenterals Limited, representing 30% of its total share capital. The acquisition was completed on January 16, 2026, making Swiss Parenterals a wholly-owned subsidiary of Eris Lifesciences.
This decision follows a Board Meeting held on November 24, 2025, and subsequent shareholder approval via postal ballot on December 24, 2025. The company had received in-principal approval for this preferential issue from NSE and BSE on January 9, 2026. The newly allotted shares will rank pari-passu with existing equity shares, subject to lock-in and transfer restrictions.
Consequent to this allotment, Eris Lifesciences' paid-up equity capital has increased to ₹13,85,23,263, comprising 13,85,23,263 equity shares, from the previous ₹13,62,16,891, consisting of 13,62,16,891 equity shares. The new shares are expected to be listed on the NSE and BSE upon receiving the necessary approvals.
What to do with a filing like this
Eris Lifesciences Limited filed this with the NSE as a statutory disclosure, categorised under equity fundraising. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Eris Lifesciences Limited. Read the original for the full detail.